Infectious Disease Clinics of North America volume 23, issue 4, P983-996 2009 DOI: 10.1016/j.idc.2009.06.007 View full text
|
|
Share
Jose A. Bazan, Stanley I. Martin, Kenneth M. Kaye

Abstract: This article reviews the new beta-lactam (beta-lactam) antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. At this writing, ceftobiprole is under review by the FDA for approval based on results of phase 3 clinical trials, wherea…

expand abstract